WO2007027614A3 - Abnormal glycosylation in tamm-horsfall protein in interstitial cystitis patient - Google Patents

Abnormal glycosylation in tamm-horsfall protein in interstitial cystitis patient Download PDF

Info

Publication number
WO2007027614A3
WO2007027614A3 PCT/US2006/033544 US2006033544W WO2007027614A3 WO 2007027614 A3 WO2007027614 A3 WO 2007027614A3 US 2006033544 W US2006033544 W US 2006033544W WO 2007027614 A3 WO2007027614 A3 WO 2007027614A3
Authority
WO
WIPO (PCT)
Prior art keywords
tamm
interstitial cystitis
horsfall protein
abnormal glycosylation
cystitis patient
Prior art date
Application number
PCT/US2006/033544
Other languages
French (fr)
Other versions
WO2007027614A2 (en
Inventor
C Lowell Parsons
Original Assignee
Univ California
C Lowell Parsons
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, C Lowell Parsons filed Critical Univ California
Priority to EP06802487A priority Critical patent/EP1919496A2/en
Publication of WO2007027614A2 publication Critical patent/WO2007027614A2/en
Publication of WO2007027614A3 publication Critical patent/WO2007027614A3/en
Priority to US12/002,056 priority patent/US20090023637A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/348—Urinary tract infections

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method for inhibiting Interstitial Cystitis and its symptoms, reducing symptoms of Interstitial Cystitis in a subject and repairing the mucin layer in a subject by administering an effective amount of a Tamm-Horsfall protein to the subject.
PCT/US2006/033544 2005-08-30 2006-08-30 Abnormal glycosylation in tamm-horsfall protein in interstitial cystitis patient WO2007027614A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06802487A EP1919496A2 (en) 2005-08-30 2006-08-30 Abnormal glycosylation in tamm-horsfall protein in interstitial cystitis patient
US12/002,056 US20090023637A1 (en) 2006-08-30 2007-12-14 Methods for detecting and treating interstitial cystitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71263205P 2005-08-30 2005-08-30
US60/712,632 2005-08-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/002,056 Continuation-In-Part US20090023637A1 (en) 2006-08-30 2007-12-14 Methods for detecting and treating interstitial cystitis

Publications (2)

Publication Number Publication Date
WO2007027614A2 WO2007027614A2 (en) 2007-03-08
WO2007027614A3 true WO2007027614A3 (en) 2007-06-28

Family

ID=37632145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033544 WO2007027614A2 (en) 2005-08-30 2006-08-30 Abnormal glycosylation in tamm-horsfall protein in interstitial cystitis patient

Country Status (2)

Country Link
EP (1) EP1919496A2 (en)
WO (1) WO2007027614A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780398A2 (en) * 1995-12-14 1997-06-25 JCR PHARMACEUTICALS Co., LTD. Process for purifying tammhorsfall glycoprotein or uromodulin, their purified products and method for making the discrimination between both of them
US6290959B1 (en) * 1996-10-24 2001-09-18 New York University Method for screening compounds for inhibiting bacterial attachment to host cell receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780398A2 (en) * 1995-12-14 1997-06-25 JCR PHARMACEUTICALS Co., LTD. Process for purifying tammhorsfall glycoprotein or uromodulin, their purified products and method for making the discrimination between both of them
US6290959B1 (en) * 1996-10-24 2001-09-18 New York University Method for screening compounds for inhibiting bacterial attachment to host cell receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKIYAMA A ET AL: "Urothelial cytoprotective activity of Tamm-Horsfall protein isolated from the urine of healthy subjects and patients with interstitial cystitis.", INTERNATIONAL JOURNAL OF UROLOGY : OFFICIAL JOURNAL OF THE JAPANESE UROLOGICAL ASSOCIATION MAY 2000, vol. 7, no. 5, May 2000 (2000-05-01), pages 176 - 183, XP009077559, ISSN: 0919-8172 *
PARSONS C LOWELL: "Interstitial cystitis: epidemiology and clinical presentation.", CLINICAL OBSTETRICS AND GYNECOLOGY MAR 2002, vol. 45, no. 1, March 2002 (2002-03-01), pages 242 - 249, XP009077582, ISSN: 0009-9201 *
PARSONS ET AL: "CYTO-INJURY FACTORS IN URINE: A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF INTERSTITIAL CYSTITIS", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 164, no. 4, October 2000 (2000-10-01), pages 1381 - 1384, XP005553807, ISSN: 0022-5347 *
SERAFINI-CESSI FRANCA ET AL: "N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases.", GLYCOCONJUGATE JOURNAL NOV 2005, vol. 22, no. 7-9, November 2005 (2005-11-01), pages 383 - 394, XP019207060, ISSN: 0282-0080 *

Also Published As

Publication number Publication date
EP1919496A2 (en) 2008-05-14
WO2007027614A2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2008054208A3 (en) Use of nutritional compositions for preventing disorders
WO2007133721A3 (en) Food compositions and methods of treating periodontal disease
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2009109908A8 (en) Methods of treating inflammatory pain
WO2009118722A3 (en) Methods and compositions for oral administration of proteins
MX2010006823A (en) Methods for the treatment of gout.
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
WO2007143674A3 (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
AU2010212865A8 (en) SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
WO2007117971A3 (en) Ocular allergy treatments
WO2007095288A3 (en) Methionine-containing protein or peptide compositions and methods of making and using
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2008021861A3 (en) Rehydration beverage
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
MX2008012479A (en) Treatment of neurodegenerative diseases.
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2008127654A3 (en) Methods and compositions for intra-articular coagulation proteins
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
WO2007129114A3 (en) Aptamers directed to recombinant muc1
WO2007144057A3 (en) Antimicrobial carbon
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
WO2008100629A3 (en) Glutathione peroxidase mimetics for the treatment of dermatoses
WO2007121279A3 (en) Cancer treatment method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006802487

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE